K

Kardigan

Biotech firm developing cardiovascular medicines

Vice President, Clinical Development

Full-Time
$340k - $416k
Expert
MD
Princeton, NJ, USA
Remote
Biology & Biotech

About the job

Requirements
  • An MD or equivalent medical degree is required; board certification and clinical practice experience are a plus. Cardiology or cardiometabolic specialization is welcome but not required.
  • 10–15+ years of clinical development experience within biotechnology and/or pharmaceutical companies, including substantial hands-on experience in biotech or emerging-company settings.
  • Substantial Phase 2b and Phase 3 experience, including designing and leading late-stage and/or registrational studies through execution and data readout.
  • Demonstrated experience serving as clinical lead for a major drug program or asset, ideally through key late-stage development milestones.
  • Demonstrated strength in protocol development, including hands-on authorship of clinical protocols and amendments from concept through approval.
  • Proven experience recruiting, managing, mentoring, and developing clinical development physicians and scientists.
  • Experience in a high-growth or emerging biotech environment, and a track record of effective partnership with a CMO or senior medical leadership.
  • Proven ability to lead cross-functional teams across clinical, regulatory, biometrics, data management, and clinical operations, driving alignment on a unified development plan while safeguarding scientific and analytical integrity.
  • Proven leadership in managing a cross-functional, matrixed team to develop and implement a program-wide clinical development plan, including scenario planning, assessment of clinical trial design scenarios for commercial/medical launch strategy and therapeutic adoption, partnership with Biometrics on evidence generation strategy, and partnership with Clinical Operations on operational strategy.
  • Deep end-to-end development experience, including phase-appropriate study design, dose and population selection, endpoint strategy, and a clear understanding of the evidentiary requirements for regulatory approval.
  • Demonstrated success developing and defending regulatory strategy, including preparation of evidence packages and translation of Health Authority feedback into concrete design decisions on endpoints, multiplicity, and analysis populations.
  • Experience establishing pre-specified go/no-go criteria and success thresholds prior to data availability, with a working command of the distinction between statistical significance and clinically meaningful effect.
  • Experience in statistical concepts and trial designs, including estimands, interim analyses, and sources of bias, with sufficient therapeutic-area and patient-population knowledge to critically evaluate emerging data, identify anomalies, and translate clinical findings into program decisions.
  • Strong patient-centric orientation and commitment to ensuring clinical development strategies ultimately serve patients and their families.
  • Flexibility to travel as needed for scientific meetings, investigator engagement, and health authority interactions.
Responsibilities
  • Serve as the Clinical Development Lead for the Danicamtiv program, with end-to-end accountability for clinical development strategy and execution.
  • Own the Clinical Development Plan and clinical program strategy, ensuring alignment with the overall program strategy set by the Global Program Team and Kardigan’s wider development goals.
  • Co-lead the Global Clinical Team and serve as a core member of the Global Program Team, representing the clinical program in governance forums and ensuring cross-functional alignment on clinical priorities, timelines, and decisions.
  • Own the clinical protocol as a program deliverable and lead protocol design, with critical input into indication selection and Target Product Profile development. The Clinical Development Medical Director owns the scientific and clinical content of the protocol; the Clinical Scientist leads drafting and amendment activities.
  • Hold accountability for clinical program-level execution, budget, and timelines, in partnership with the Clinical Operations Program Lead, who owns operational budget build and roll-up.
  • Lead clinical decision-making based on emerging data, benefit–risk assessments, and evolving regulatory expectations; partner with the Statistics Program Lead on pre-specified go/no-go criteria and success thresholds; recommend go/no-go decisions and ensure patient safety remains the foremost consideration.
  • Partner with Drug Safety & Pharmacovigilance on ongoing safety surveillance, signal evaluation, and benefit–risk communication for the program, and provide medical oversight of medical monitoring activities.
  • Partner with colleagues from Clinical Operations, Biometrics, Regulatory Affairs, and Medical Affairs to ensure seamless oversight and execution of clinical trials across the program.
  • Support Medical Affairs on publication planning, congress presentations, and scientific communication of clinical data, ensuring accuracy and scientific integrity.
  • Lead the clinical dimensions of the alliance relationship where the program involves an in-licensing or alliance partner.
  • Ensure clinical development activities comply with Good Clinical Practice, applicable regulations, and Kardigan policies and standard operating procedures, upholding patient safety, ethics, and scientific integrity.
  • Line manage the Clinical Development Medical Director and Clinical Scientist for the program; oversee their performance, development, day-to-day prioritization, and appropriate resource management across the program.
  • Recruit, manage, mentor, and develop clinical development physicians and scientists as the program team grows; lead the search for a Medical Director when that role is open at the point of hire.
  • Act as the primary clinical development point of contact for regulatory interactions, and provide clinical leadership for health authority meetings and submission content in partnership with Regulatory Affairs.
  • Present clinical strategy, study progress, and risks to internal leadership and, when needed, to the Kardigan Executive Committee and Board of Directors, with clear, balanced framing of data and uncertainties.
  • Identify and build relationships with key opinion leaders, academic institutions, and investigators to inform development strategy, shape trial design, and support site selection and advisory board engagement.
  • Represent the Kardigan clinical development function externally at scientific meetings, advisory boards, and interactions with key opinion leaders related to the program and potentially other Kardigan programs, ensuring external scientific exchange is accurate, balanced, and compliant with applicable regulations and industry codes.
Desired Qualifications
  • Experience taking a program through Phase 3 to registration/NDA is strongly preferred.
  • Board certification and clinical practice experience are a plus.
  • Cardiology or cardiometabolic specialization is welcome but not required.

About the company

Kardigan develops medicines to prevent and treat cardiovascular disease. It focuses on discovering and developing multiple cardiovascular therapies at a rapid pace, using deep expertise in heart-health drug development to move candidates from research toward commercialization. Their product approach centers on creating medicines that address heart disease more effectively and earlier in the disease process. Kardigan differentiates itself through a leadership team of seasoned biopharma veterans and a commitment to modernizing how cardiovascular drugs are discovered and developed, aiming to bring therapies to patients faster and more efficiently. The company’s goal is to reduce the global burden of cardiovascular disease by providing safe, effective medicines that prevent progression or cure conditions related to heart health.

Company Size

201-500

Company Stage

IPO

Headquarters

West Windsor Township, New Jersey

Founded

2023

Get referred to Kardigan

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 IPO raised $460 million gross, lifting cash to $660.7 million.
  • August 2026: KINSHIP-DCM Phase 3 started, while KARDINAL-ASH enrolled its first patient.
  • ESC 2026 presentations and 1H 2027 topline data keep multiple catalysts ahead.

What critics are saying

  • Kardigan reported $116.2 million Q2 2026 losses, burning IPO cash quickly.
  • All three programs need successful 1H 2027 readouts; one failure could erase valuation.
  • No product revenue exists; another financing round before 2028 would dilute shareholders.

What makes Kardigan unique

  • Tassos Gianakakos and Jay Edelberg built MyoKardia’s mavacamten playbook, then Kardigan.
  • Kardigan pairs Prolaio AI with late-stage cardio trials for narrower, faster registrational studies.
  • Danicamtiv, ataciguat, and tonlamarsen target separate unmet cardiovascular niches without approved therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

19%

2 year growth

34%
U.S. Securities and Exchange Commission
Oct 20th, 2026
Final Prospectus 424(b)(4)

Filed Pursuant to Rule 424(b)(4)Registration No. 333-296236 and 333-296870

MarketScreener
Jun 18th, 2026
Kardigan makes strong Nasdaq debut following upsized IPO.

Kardigan makes strong Nasdaq debut following upsized IPO. Kardigan delivered a notable market debut on the Nasdaq, raising $400m in an upsized initial public offering. Shares of the cardiovascular treatment specialist opened at $16.25, above the $16 IPO price, before climbing more than 22% during the session. This performance underscores a resurgence in investor appetite for biotechnology firms boasting advanced clinical programs and robust growth prospects. Published on 06/18/2026 at 03:52 pm EDT Based in Princeton, New Jersey, Kardigan is developing several precision therapies for cardiovascular diseases. Its pipeline notably includes drug candidates danicamtiv, ataciguat, and tonlamarsen. Management has indicated that pivotal data regarding these three programs are expected during the first half of next year. The company was founded by Tassos Gianakakos and Jay Edelberg, two former executives who played key roles in the development of the heart medication mavacamten at MyoKardia, which was acquired by Bristol Myers Squibb for $13bn in 2020. This transaction takes place within a more favorable environment for biotech IPOs following several years defined by tighter access to capital. However, analysts point out that Kardigan may require additional financing in the medium term. The company stated in its regulatory filings that its current resources would not be sufficient to fund operations for at least twelve months without further capital injections, even though the funds raised are intended to accelerate the development of its clinical programs. (C) MarketScreener.com - 2026

IPO Scoop
Jun 18th, 2026
Kardigan

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.

StockTitan
Jun 18th, 2026
Kardigan prices upsized $400M IPO at $16 per share on Nasdaq

Kardigan, a clinical-stage precision therapeutics company developing treatments for cardiovascular diseases, has priced its initial public offering of 25 million shares at $16 per share. The offering is expected to generate gross proceeds of $400 million before underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase an additional 3.75 million shares. Kardigan's shares are expected to begin trading on the Nasdaq Global Market on 18 June 2026 under the ticker symbol "KARD", with the offering closing on 22 June 2026. J.P. Morgan Securities, Jefferies, Leerink Partners and TD Securities are serving as underwriters. Based in South San Francisco and Princeton, Kardigan focuses on developing medicines targeting cardiovascular diseases without approved treatments.

pharmaphorum
Jun 18th, 2026
Heart drug biotech Kardigan raises $400m in upscaled IPO.

Heart drug biotech Kardigan raises $400m in upscaled IPO. Cardiovascular drug developer Kardigan has completed its IPO, and in common with the prevailing trend in Nasdaq listings this year, has raised substantially more than it originally anticipated. The gross proceeds have come in at around $400 million, with 25 million shares sold for $16 apiece, which compares to Kardigan's earlier objective of selling 23.3 million at a range of $14 to $16. The final tally could be increased by another $60 million or so if underwriters take up an option to buy another 3.75 million shares at the final price. The proceeds - which top up cash reserves of around $287 million held by Kardigan at the end of March - will go towards the company's three clinical-stage drug candidates, which are all in late-stage development, along with R&D and general corporate purposes. Between $80 million and $90 million is earmarked for danicamtiv, an oral cardiac myosin activator for dilated cardiomyopathy (DCM) driven by MYH7 and TTN gene variants in genes coding for the sarcomere, the functional unit of muscle tissue. That should allow Kardigan to complete an ongoing phase 2b trial and the start of phase 3 development, according to its IPO prospectus. The company has allocated the same amount to ataciguat, a once-daily, oral soluble guanylate cyclase (sGC) activator for calcific aortic valve stenosis (CAVS), and $40 million to $50 million for tonlamarsen, an angiotensinogen-targeted subcutaneous antisense oligonucleotide for blood pressure management in acute severe hypertension (ASH). Once again, that should fund the completion of ongoing phase 2b studies of the two drugs and the start of phase 3, with another $50 million to $60 million pledged to other R&D activities. That includes the further development of its Prolaio platform for applying AI to cardiovascular drug development, which it acquired for up to $200 million. Phase 2b data from the KINSHIP-DCM trial of danicamtiv is due in the first half of 2027, with a series of readouts from the KATALYST-AV study of ataciguat and the KARDINAL study of tonlamarsen also expected next year. Founded by former executives from MyoKardia - which was bought by Bristol Myers Squibb for $13.1 billion in 2020 - Kardigan is based in Princeton, New Jersey, with a second site in South San Francisco. Kardigan's stock is due to start trading on the Nasdaq tomorrow under the KARD ticker symbol. 18 June, 2026